Year-end Sale % OFF 
Abstract
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma therapy in adults. Clinical experience in pediatric lymphoma patients is still very limited. This review outlines the rationale for antibody treatment of B-cell lymphomas in children and describes potential target structures on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-cell lymphoma in children and gives an outlook on new developments and challenges for antibody therapy of pediatric B-cell lymphoma.
Highlights
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies
The optimal B-cell lymphoma target antigen should be expressed on the cell surface, so it can be reached by the antibody
The anti-CD21 antibody-131Iconjugate 131I-OKB7 was evaluated in a phase I study in 18 adult lymphoma patients
Summary
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease.Therapeutic toxicity remains high calling for better targeted and less toxic therapies. A CD19 antibody-drug conjugate (SAR3419) has recently been tested in a phase I trial in adult lymphoma patients (Younes et al, 2012a). High CD21 expression on lymphomas has been shown to inhibit internalization of anti-CD19 antibodies into lymphoma cells leading to reduced efficacy of anti-CD19-drug conjugates (Ingle et al, 2008).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
